RESUMEN
PURPOSE: To evaluate the tissue content of neutral and acidic mucins, sulfomucins and sialomucins in colonic glands devoid of intestinal transit after enemas containing sucralfate and n-acetylcysteine alone or in combination. METHODS: Sixty-four rats underwent intestinal transit bypass. A colonic segment was collected to compose the white group (without intervention). After derivation, the animals were divided into two groups according to whether enemas were performed daily for two or four weeks. Each group was subdivided into four subgroups according to the substance used: control group: saline 0.9%; sucralfate group (SCF): SCF 2 g/kg/day; n-acetylcysteine group (NAC): NAC 100 mg/kg/day; and SCF+NAC group: SCF 2 g/kg/day + NAC 100 mg/kg/day.Neutral and acidic mucins were stained by periodic acid-Schiff and alcian-blue techniques, respectively. The distinction between sulfomucins and sialomucin was made by the high alcian-blue iron diamine technique. The content of mucins in the colonic glands was measured by computerized morphometry. The inflammatory score was assessed using a validated scale. The results between the groups were compared by the Mann-Whitney's test, while the variation according to time by the Kruskal-Wallis' test (Dunn's post-test). A significance level of 5% was adopted. RESULTS: There was reduction in the inflammatory score regardless of the application of isolated or associated substances. Intervention with SCF+NAC increased the content of all mucin subtypes regardless of intervention time. CONCLUSIONS: The application of SCF+NAC reduced the inflammatory process of the colonic mucosa and increased the content of different types of mucins in the colonic glands of segments excluded from fecal transit.
Asunto(s)
Colitis , Sucralfato , Ratas , Animales , Sucralfato/farmacología , Sucralfato/uso terapéutico , Acetilcisteína/farmacología , Ratas Wistar , Colon , Colitis/tratamiento farmacológico , Colitis/prevención & control , Mucinas , Sialomucinas , Mucosa Intestinal , Enema/métodosRESUMEN
AIM: Oxidative stress is one of the main mechanisms associated with the rupture of the defense mechanisms of the colonic epithelial barrier; it reduces the tissue content of the claudin-3 and occludin proteins, which are the main constituents of intercellular tight junctions. Sucralfate (SCF) has antioxidant activity and has been used to treat different forms of colitis. This study aimed to measure the tissue claudin-3 and occludin content of the colon mucosa without fecal transit, subjected to intervention with SCF. METHODS: Thirty-six rats were subjected to left colon colostomy and distal mucous fistula. They were divided into two groups according to euthanasia that was performed 2 or 4 weeks after the intervention. Each group was divided into three subgroups according to the enema applied daily: saline alone, SCF at 1 g/kg/day, or SCF at 2 g/kg/day. Colitis was diagnosed by the histological analysis adopting the previous validate scale. The tissue expression of both proteins was identified by immunohistochemical technique. The content of proteins was quantified by computer-assisted image analysis. RESULTS: The inflammatory score was high in colonic segments without fecal transit, and enemas with SCF reduced the inflammatory score in these segments, mainly in those animals submitted to intervention with SCF in greater concentration and for a longer period of intervention. There was an increase in tissue content of claudin-3 and occludin, related to SCF concentration. The tissue content of both proteins was not related to the intervention time. CONCLUSION: Enemas with SCF reduced the inflammation and increased the tissue content of claudin-3 and occludin in colonic mucosa without fecal stream.
OBJETIVO: O estresse oxidativo é um dos principais mecanismos associados à ruptura dos mecanismos de defesa que formam a barreira epitelial cólica e reduz o conteúdo tecidual das proteínas claudina-3 e ocludina principais constituintes das junções de oclusão intercelulares. O sucralfato, possui atividade antioxidante e tem sido usado para tratar diferentes formas de colite. Mensurar o conteúdo tecidual de claudina-3 e ocludina da mucosa do cólon sem trânsito fecal, submetido à intervenção com sucralfato. MÉTODO: Trinta e seis ratos foram submetidos à colostomia do cólon esquerdo e fístula mucosa distal. Os animais foram divididos em dois grupos de acordo com a eutanásia ser realizada duas ou quatro semanas após a intervenção. Cada grupo foi dividido em três subgrupos de acordo com o tipo de intervenção realizada diariamente: solução salina isolada; sucralfato a 1 g/kg/dia ou sucralfato a 2g/kg/dia. A colite foi diagnosticada por análise histológica adotando escala de validação prévia. A expressão tecidual de ambas as proteínas foi identificada por imunoistoquímica. O conteúdo das proteínas foi quantificado por análise de imagem assistida por computador. RESULTADOS: O escore inflamatório foi maior nos segmentos cólicos sem trânsito fecal e os enemas com sucralfato reduziram o escore inflamatório nesses segmentos, principalmente nos animais submetidos à intervenção com sucralfato em maior concentração e por período mais longo de intervenção. Houve aumento no conteúdo tecidual das proteínas claudina-3 e ocludina, relacionado com a concentração de sucralfato. O conteúdo tecidual de ambas as proteínas não se modificou com a duração da intervenção. CONCLUSÃO: Enemas com sucralfato reduzem a inflamação e aumentam o conteúdo tecidual de claudina-3 e ocludina na mucosa cólica sem trânsito intestinal.
Asunto(s)
Colitis , Sucralfato , Animales , Colitis/tratamiento farmacológico , Colitis/prevención & control , Enema , Ratas , Ratas Wistar , Sucralfato/uso terapéuticoRESUMEN
RESUMO - RACIONAL: O estresse oxidativo é um dos principais mecanismos associados à ruptura dos mecanismos de defesa que formam a barreira epitelial cólica e reduz o conteúdo tecidual das proteínas claudina-3 e ocludina principais constituintes das junções de oclusão intercelulares. O sucralfato, possui atividade antioxidante e tem sido usado para tratar diferentes formas de colite. OBJETIVO: Mensurar o conteúdo tecidual de claudina-3 e ocludina da mucosa do cólon sem trânsito fecal, submetido à intervenção com sucralfato. MÉTODO: Trinta e seis ratos foram submetidos à colostomia do cólon esquerdo e fístula mucosa distal. Os animais foram divididos em dois grupos de acordo com a eutanásia ser realizada duas ou quatro semanas após a intervenção. Cada grupo foi dividido em três subgrupos de acordo com o tipo de intervenção realizada diariamente: solução salina isolada; sucralfato a 1 g/kg/dia ou sucralfato a 2g/kg/dia. A colite foi diagnosticada por análise histológica adotando escala de validação prévia. A expressão tecidual de ambas as proteínas foi identificada por imunoistoquímica. O conteúdo das proteínas foi quantificado por análise de imagem assistida por computador. RESULTADOS: O escore inflamatório foi maior nos segmentos cólicos sem trânsito fecal e os enemas com sucralfato reduziram o escore inflamatório nesses segmentos, principalmente nos animais submetidos à intervenção com sucralfato em maior concentração e por período mais longo de intervenção. Houve aumento no conteúdo tecidual das proteínas claudina-3 e ocludina, relacionado com a concentração de sucralfato. O conteúdo tecidual de ambas as proteínas não se modificou com a duração da intervenção. CONCLUSÃO: Enemas com sucralfato reduzem a inflamação e aumentam o conteúdo tecidual de claudina-3 e ocludina na mucosa cólica sem trânsito intestinal.
ABSTRACT - BACKGROUND: Oxidative stress is one of the main mechanisms associated with the rupture of the defense mechanisms of the colonic epithelial barrier; it reduces the tissue content of the claudin-3 and occludin proteins, which are the main constituents of intercellular tight junctions. Sucralfate (SCF) has antioxidant activity and has been used to treat different forms of colitis. AIM: This study aimed to measure the tissue claudin-3 and occludin content of the colon mucosa without fecal transit, subjected to intervention with SCF. METHODS: Thirty-six rats were subjected to left colon colostomy and distal mucous fistula. They were divided into two groups according to euthanasia that was performed 2 or 4 weeks after the intervention. Each group was divided into three subgroups according to the enema applied daily: saline alone, SCF at 1 g/kg/day, or SCF at 2 g/kg/day. Colitis was diagnosed by the histological analysis adopting the previous validate scale. The tissue expression of both proteins was identified by immunohistochemical technique. The content of proteins was quantified by computer-assisted image analysis. RESULTS: The inflammatory score was high in colonic segments without fecal transit, and enemas with SCF reduced the inflammatory score in these segments, mainly in those animals submitted to intervention with SCF in greater concentration and for a longer period of intervention. There was an increase in tissue content of claudin-3 and occludin, related to SCF concentration. The tissue content of both proteins was not related to the intervention time. CONCLUSION: Enemas with SCF reduced the inflammation and increased the tissue content of claudin-3 and occludin in colonic mucosa without fecal stream.
Asunto(s)
Animales , Ratas , Sucralfato/uso terapéutico , Colitis/prevención & control , Colitis/tratamiento farmacológico , Ratas Wistar , EnemaRESUMEN
Control of hyperphosphatemia is an important part of the management of chronic kidney disease (CKD). The purpose of this study was to determine the efficacy of sucralfate as a phosphate binder in normal cats and normophosphatemic CKD cats. A 500 mg sucralfate slurry was administered orally q 8 hr for 2 wk, and serum phosphorus, urine fractional excretion of phosphorus, and fecal phosphorus concentrations were measured. In normal cats treated with sucralfate, significant changes in serum phosphorus concentration or urinary excretion of phosphorus were not detected, and vomiting occurred after 14.7% of administrations. Of the five normophosphatemic cats with CKD treated with sucralfate, three experienced clinical decompensation, including vomiting, anorexia, constipation, and increased azotemia. Administration of sucralfate did not result in significant changes in fecal phosphorus concentration in these cats. The effects of sucralfate administration on serum phosphorus concentration and urinary excretion of phosphorus in CKD cats was difficult to determine because of dehydration and worsening azotemia associated with decompensation. Due to side effects and the apparent lack of efficacy of the medication, the study was discontinued. This study was unable to confirm efficacy of this sucralfate formulation as a phosphate binder, and side effects were problematic during the study.
Asunto(s)
Enfermedades de los Gatos/tratamiento farmacológico , Gatos/metabolismo , Fósforo/sangre , Insuficiencia Renal Crónica/veterinaria , Sucralfato/uso terapéutico , Animales , Antiulcerosos/uso terapéutico , Enfermedades de los Gatos/sangre , Femenino , Masculino , Fósforo/orina , Insuficiencia Renal Crónica/tratamiento farmacológicoRESUMEN
PURPOSE: To measure the content of acidic mucin, sialomucin, and sulfomucins in the colonic mucosa without fecal stream submit to intervention with sucralfate (SCF).METHODS: Thirty-six rats were submitted to a right colostomy and a distal mucous fistula and divided into two groups according to sacrifice to be performed two or four weeks. Each group was divided into three subgroups according daily application of enemas containing saline, SCF at 1.0 g/kg/day or 2.0 g/kg/day. Colitis was diagnosed by histological analysis. Acid mucins were determined with the Alcian-Blue and sulfomucin and sialomucin by high iron diamine-alcian blue (HID-AB) techniques. The mucins were quantified by computer-assisted image analysis. Mann-Whitney and ANOVA tests were used to analyze the results establishing the level of significance of 5% for both (p 0.05).RESULTS: SCF enemas decreased the inflammation score and was related to the concentration used and time of the intervention. SCF at both concentrations increased the content of acid mucin, which was related to the concentration used and to the improvement in the inflammatory score. There was an increase in the content of sulfomucins and sialomucins in SCF groups. SCF increased sulfomucins from 2 weeks of intervention, which was not related to the dose or time of application. The increase in sialomucin content was related to the time and dose used in the intervention.CONCLUSION: Sucralfate increased the content of acidic mucins, primarily at the expense of sialomucin, which was affected by the dose and time of intervention.(AU)
Asunto(s)
Animales , Ratas , Sialomucinas/análisis , Mucinas , Sucralfato/uso terapéutico , Colon , Colitis/terapia , Procesamiento de Imagen Asistido por ComputadorRESUMEN
PURPOSE: To evaluate the effects of sucralfate on tissue content of neutral and acids mucins in rats with diversion colitis. METHODS: Thirty-six rats were submitted to a proximal right colostomy and a distal mucous fistula. They were divided into two groups according to sacrifice to be performed two or four weeks after intervention. Each group was divided into three subgroups according daily application of enemas containing saline, sucralfate at 1.0 g/kg/day or 2.0 g/kg/day. Colitis was diagnosed by histological analysis and neutral and acid mucins by Periodic Acid Schiff and Alcian Blue techniques, respectively. The contents of mucins were quantified by computer-assisted image analysis. Student's t paired and ANOVA test were used to compare the contents of both types of mucins among groups, and to verify the variance with time, establishing level of signification of 5% for both (p<0.05). RESULTS: Enemas containing sucralfate improves the inflammation and increases the tissue contents of neutral and acid mucins. The content of neutral mucins does not change with the time or concentration of sucralfate used, while acid mucins increases with concentration and time of intervention. CONCLUSIONS: Sucralfate enemas improve the inflammatory process and increase the tissue content of neutral and acid mucins in colon without fecal stream.
Asunto(s)
Antiulcerosos/uso terapéutico , Colitis/tratamiento farmacológico , Enema/métodos , Glicoproteínas de Membrana/análisis , Mucinas/análisis , Sucralfato/uso terapéutico , Animales , Antiulcerosos/farmacología , Colitis/patología , Colon/efectos de los fármacos , Colon/patología , Modelos Animales de Enfermedad , Procesamiento de Imagen Asistido por Computador , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/patología , Masculino , Mucinas/efectos de los fármacos , Ratas Wistar , Reproducibilidad de los Resultados , Sucralfato/farmacología , Factores de Tiempo , Resultado del TratamientoRESUMEN
PURPOSE: To evaluate the effects of sucralfate on tissue content of neutral and acids mucins in rats with diversion colitis. METHODS: Thirty-six rats were submitted to a proximal right colostomy and a distal mucous fistula. They were divided into two groups according to sacrifice to be performed two or four weeks after intervention. Each group was divided into three subgroups according daily application of enemas containing saline, sucralfate at 1.0 g/kg/day or 2.0 g/kg/day. Colitis was diagnosed by histological analysis and neutral and acid mucins by Periodic Acid Schiff and Alcian Blue techniques, respectively. The contents of mucins were quantified by computer-assisted image analysis. Student's t paired and ANOVA test were used to compare the contents of both types of mucins among groups, and to verify the variance with time, establishing level of signification of 5% for both (p<0.05). RESULTS: Enemas containing sucralfate improves the inflammation and increases the tissue contents of neutral and acid mucins. The content of neutral mucins does not change with the time or concentration of sucralfate used, while acid mucins increases with concentration and time of intervention. CONCLUSIONS: Sucralfate enemas improve the inflammatory process and increase the tissue content of neutral and acid mucins in colon without fecal stream. .
Asunto(s)
Animales , Masculino , Antiulcerosos/uso terapéutico , Colitis/tratamiento farmacológico , Enema/métodos , Glicoproteínas de Membrana/análisis , Mucinas/análisis , Sucralfato/uso terapéutico , Antiulcerosos/farmacología , Colitis/patología , Colon/efectos de los fármacos , Colon/patología , Modelos Animales de Enfermedad , Procesamiento de Imagen Asistido por Computador , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/patología , Mucinas/efectos de los fármacos , Ratas Wistar , Reproducibilidad de los Resultados , Sucralfato/farmacología , Factores de Tiempo , Resultado del TratamientoRESUMEN
PURPOSE:To evaluate the effects of sucralfate on tissue content of neutral and acids mucins in rats with diversion colitis.METHODS:Thirty-six rats were submitted to a proximal right colostomy and a distal mucous fistula. They were divided into two groups according to sacrifice to be performed two or four weeks after intervention. Each group was divided into three subgroups according daily application of enemas containing saline, sucralfate at 1.0 g/kg/day or 2.0 g/kg/day. Colitis was diagnosed by histological analysis and neutral and acid mucins by Periodic Acid Schiff and Alcian Blue techniques, respectively. The contents of mucins were quantified by computer-assisted image analysis. Student's t paired and ANOVA test were used to compare the contents of both types of mucins among groups, and to verify the variance with time, establishing level of signification of 5% for both (p<0.05).RESULTS:Enemas containing sucralfate improves the inflammation and increases the tissue contents of neutral and acid mucins. The content of neutral mucins does not change with the time or concentration of sucralfate used, while acid mucins increases with concentration and time of intervention.CONCLUSIONS:Sucralfate enemas improve the inflammatory process and increase the tissue content of neutral and acid mucins in colon without fecal stream.(AU)
Asunto(s)
Animales , Ratas , Enema/métodos , Enema/veterinaria , Sucralfato/uso terapéutico , Mucinas , Colitis/terapia , Colostomía/veterinaria , Procesamiento de Imagen Asistido por ComputadorRESUMEN
Diversion colitis (DC) is an inflammatory disease that develops in segments with fecal diversion. Sucralfate (SCF) complex, which consists of sucrose octasulfate and polyaluminum hydroxide, has been demonstrated to be effective in the treatment of different forms of colitis. However, until now, the effects of SCF have not been evaluated in DC. OBJECTIVE: to evaluate whether the use of enemas containing SFC improves histological findings in experimental DC. METHODS: Thirty-six rats underwent right colon bypass procedure through the creation of a proximal colostomy and a distal mucous fistula. The animals were divided into two groups according to the euthanization procedure to be performed two to four weeks after surgery. Each experimental group was divided into three subgroups of six animals, which were submitted to daily application of enemas containing saline solution 0.9% or SCF at concentrations of 1.0 g/kg/day or 2.0 g/kg/day, respectively. The diagnosis of DC in segments with fecal diversion was established by histopathological study considering the following variables: epithelial loss, formation of crypt abscesses, the population of goblet cells, inflammatory infiltrate and presence of fibrosis. For statistical analysis, the nonparametric Mann-Whitney and Kruskal-Wallis tests were used, with a significance level of 5% (p <0.05). RESULTS: It was observed that the daily application of SCF enemas decreased epithelial loss, formation of colon crypt abscesses, inflammatory infiltrate and tissue fibrosis (p <0.05), unrelated to time of intervention. The intervention with SCF preserves the goblet cell population. The effects of the substance on the preservation of colonic epithelium; the decrease in the inflammatory process and subsequent abscess formation in the colon crypts are associated with the concentration used, whereas tissue fibrosis decrease is associated with the concentration and time of intervention. CONCLUSION: Preventive application of SCF enemas reduces the inflammatory process in the colon with fecal diversion. (AU)
A colite de exclusão (CE) é uma doença inflamatória que se desenvolve em segmentos desprovidos de trânsito fecal. O sucralfato (SCF) complexo formado pelo octossulfato de sacarose e hidróxido de polialumínio vem se demonstrando eficaz para o tratamento de diferentes formas de colite, porém, até a presente data, os efeitos do SCF ainda não foram avaliados na CE. OBJETIVO: avaliar se a aplicação de clisteres contendo SFC melhora as alterações histológicas encontradas em modelo experimental de CE. MÉTODOS: trinta e seis ratos foram submetidos à derivação do trânsito no cólon direito pela confecção de colostomia proximal e fístula mucosa distal. Os animais foram divididos em dois grupos experimentais de acordo com o sacrifício ser realizado após duas ou quatro semanas do procedimento cirúrgico. Cada grupo experimental foi dividido em três subgrupos de seis animais segundo terem sidos submetidos à aplicação diária com enemas contendo solução fisiológica a 0,9% ou SCF nas concentrações de 1,0g/kg/dia ou 2,0 g/kg/dia. O diagnóstico de CE nos segmentos sem trânsito foi estabelecido por estudo histopatológico considerando-se as seguintes variáveis: perda epitelial, formação de abscessos nas criptas, população de células caliciformes, infiltrado inflamatório e a presença de fibrose. Para análise estatística adotou-se os testes não paramétricos de Mann-Withney e Kruskal-Wallis estabelecendo-se para ambos, nível de significância de 5% (p < 0,05). RESULTADOS: verificou-se que a aplicação diária de enemas com SCF diminui a perda epitelial, a formação de abscessos nas criptas cólicas, o infiltrado inflamatório e a presença de fibrose tecidual (p < 0,05), não relacionada ao tempo de intervenção. A intervenção com SCF preserva a população de células caliciformes. Os efeitos da substância na preservação do epitélio cólico, na redução do processo inflamatório e consequente formação de abscessos nas criptas cólicas encontram-se relacionado à concentração utilizada, enquanto a redução da fibrose tecidual a concentração e ao tempo de intervenção. CONCLUSÃO: a aplicação preventiva de enemas com SCF reduz o processo inflamatório em segmentos cólicos desprovidos de transito intestinal. (AU)
Asunto(s)
Animales , Ratas , Sucralfato/uso terapéutico , Colitis/terapia , Colon/patología , Enema , Epitelio/lesionesAsunto(s)
Reflujo Gastroesofágico , Antiácidos/uso terapéutico , Antiulcerosos/administración & dosificación , Antiulcerosos/uso terapéutico , Ensayos Clínicos como Asunto , Endoscopía , Monitorización del pH Esofágico , Reflujo Gastroesofágico/clasificación , Reflujo Gastroesofágico/diagnóstico , Reflujo Gastroesofágico/diagnóstico por imagen , Reflujo Gastroesofágico/terapia , Antagonistas de los Receptores H2 de la Histamina/uso terapéutico , Humanos , Omeprazol/administración & dosificación , Omeprazol/uso terapéutico , Guías de Práctica Clínica como Asunto , Inhibidores de la Bomba de Protones , Radiografía , Sucralfato/uso terapéuticoRESUMEN
OBJECTIVE: The objective of this study is to evaluate the efficacy of sucralfate in alleviating posttonsilectomy morbidity in a pediatric group of patients. METHODS: A prospective, double-blind, randomized, and placebo-controlled study comparing the irrigation of a solution containing either 1g of sucralfate (study group) or 1g of lactulose (control group) was performed on 69 children aged 3-12 years, who underwent tonsillectomy at the University Hospital of Brasilia Medical School. The children were randomly assigned and each one used a solution containing sucralfate or lactulose to swish and swallow four times daily during 7 days. Eleven patients were excluded. The anesthetic was standardized and no premedication was used. Pain magnitude using an "Oucher" scale, nausea, vomiting, bleeding, earache, analgesic drug intake, changes in the interincisor teeth distance, and changes in the weight and temperature were assessed by the surgeon 6, 24h, and 7 days after the surgery. RESULTS: Patients in the study group had significantly lower pain scores in the initial 6 postoperative hours (p<0.05). The difference between the two groups was not statistically significant for the other periods following the procedure or on the evaluation of the other indices. CONCLUSIONS: The use of the sucralfate in pediatric patients undergoing tonsillectomy was not effective in reducing the postoperative morbidity according to the parameters used in this study. The surgical technique with careful mucosal dissection associated with postoperative caries could be more important in the reduction of posttonsilectomy morbidity.
Asunto(s)
Antiulcerosos/uso terapéutico , Dolor Postoperatorio/prevención & control , Sucralfato/uso terapéutico , Tonsilectomía/efectos adversos , Niño , Preescolar , Método Doble Ciego , Femenino , Humanos , Masculino , Dimensión del Dolor , Estudios Prospectivos , Irrigación Terapéutica , Resultado del TratamientoAsunto(s)
Humanos , Masculino , Femenino , Anciano , Enfermedades Gastrointestinales/tratamiento farmacológico , Anciano/fisiología , Antiácidos/uso terapéutico , Cisaprida/uso terapéutico , Enfermedades Funcionales del Colon/tratamiento farmacológico , Estreñimiento/tratamiento farmacológico , Dispepsia/tratamiento farmacológico , Metoclopramida , Misoprostol/uso terapéutico , Bombas de Protones/antagonistas & inhibidores , Sucralfato/uso terapéutico , Úlcera Péptica/tratamiento farmacológicoRESUMEN
Las tetraciclinas están descritas como antibióticos que suelen producir úlceras esofágicas. Objetivo. Ver el comportamiento de este tipo de úlceras, así como la respuesta al manejo con sucralfato. Método. Es un estudio retrospectivo de los últimos dos años donde se revisaron los casos de odinofagia y disfagia sometidos a endoscopia con antecedentes de ingesta reciente de doxiciclina. Todos fueron tratados suspendiendo la droga, mientras la gran mayoría recibieron tratamiento adicional con sucralfato 1 g cada ocho horas. Resultados. Once pacientes tuvieron como indicación: enfermedad pélvica inflamatoria, acné, infecciones urinarias y respiratorias. El síntoma más común fue odinofagia, presentándose aproximadamente 6 días después de iniciado el tratamiento con varios factores contribuyentes bien comprobados como ingesta antes de acostarse y con poco líquido. Las úlceras se caracterizaron por ser múltiples y localizadas principalmente en el tercio medio. La sintomatología en general cedió 3.7 días después de suspender los medicamentos, mientras aquellos con sucrafalto no mostraron menor duración de los síntomas. Conclusiones. Debemos ser conscientes de la inducción de úlceras por estos medicamentos, basando su tratamiento en la suspensión del antibiótico, recordando que el sucralfato puede ser parte del tratamiento ya que ha demostrado su adherencia a úlceras y lesiones esofágicas, aunque su uso no ha demostrado significancia clínica. Por ende debemos explicar las medidas prevención, como tomarlas con suficiente volumen de agua, en posición, como tomarlas con suficiente volumen de agua, en posición supina y tener precaución especial en ancianos y pacientes con patología anatómica y/o de motilidad esofágica
Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Antiulcerosos/uso terapéutico , Antibacterianos/efectos adversos , Doxiciclina/efectos adversos , Enfermedades del Esófago/inducido químicamente , Enfermedades del Esófago/diagnóstico , Enfermedades del Esófago/tratamiento farmacológico , Esofagoscopía , Factores de Riesgo , Sucralfato/uso terapéutico , Tetraciclina/efectos adversos , Úlcera/diagnóstico , Úlcera/inducido químicamente , Úlcera/tratamiento farmacológicoRESUMEN
Una mujer de 25 años de edad se presentó con odinofagia y dolor retroesternal de aparición súbita. Había ingerido metronidazol 500 mg cada 8 horas durante 3 días previos y la última tableta fue ingerida la noche anterior sin líquido antes de dormir. La esofagoscopía demostró dos úlceras circunferenciales en el tercio medio del esófago. El tratamiento consistió en suspender el metronidazol, tomar sucralfato pulverizado 2 g cada 12 horas y dieta líquida con curación clínica y endoscópica a los 7 días. Consideramos importante informar este caso dada la administración frecuente de este medicamento en México
Asunto(s)
Humanos , Femenino , Adulto , Antiulcerosos/efectos adversos , Antiulcerosos/uso terapéutico , Enfermedades del Esófago/inducido químicamente , Enfermedades del Esófago/diagnóstico , Esofagoscopía , Metronidazol/efectos adversos , Sucralfato/uso terapéutico , Úlcera/diagnóstico , Úlcera/inducido químicamente , Úlcera/tratamiento farmacológicoRESUMEN
A 25 years old female, previously in good health, complained of odinophagia and retrosternal pain. The last 3 days, she has been ingesting metronidazole 500 mg t.i.d. Last pill was swallowed the night before without liquids, at bed time. Esophagoscopy showed two ulcers in the middle portion of the esophagus. The patient stopped the medication, received liquid diet and sucralfate 2 g b.i.d. Clinically and endoscopically healing was achieved one week later. This case is important due to the high frequency of metronidazole prescription in Mexico.
Asunto(s)
Antiinfecciosos/efectos adversos , Enfermedades del Esófago/inducido químicamente , Metronidazol/efectos adversos , Úlcera/inducido químicamente , Adulto , Antiulcerosos/uso terapéutico , Enfermedades del Esófago/diagnóstico , Enfermedades del Esófago/tratamiento farmacológico , Esofagoscopía , Femenino , Humanos , Sucralfato/uso terapéutico , Úlcera/diagnóstico , Úlcera/tratamiento farmacológicoRESUMEN
UNLABELLED: Tetracycline is known as one of the antibiotics that induce esophageal ulcers. PURPOSE: Understand how these ulcers may behave and respond to treatment with sucralfate. METHOD: During the last two years we studied all patients complaining of dysphagia and odinophagia with an upper GI endoscopy, who were taking doxycycline in the last few days. All of them discontinued the drug once the diagnosis was done and most of them were treated also with sucralfate, 1 g tid. RESULTS: Eleven patients took doxycycline prescribed for: pelvic inflammatory disease, acne, urinary tract and pulmonary infections. Odinophagia was the most common symptom over the next few days of treatment with some risk factors previously documented, such as taking pills just before bedtime and with a small amount of water. The esophageal ulcers were multiple and located mainly in the middle esophageal third. Symptoms disappeared 3.7 days after the medication was stopped, while those taking sucralfate did not change the period of symptoms. CONCLUSIONS: Physicians must be aware of the doxycycline induced esophageal ulcers and discontinuation of the antibiotic as the main treatment, while sucralfate even though has shown to cover these ulcers, does not change the outcome. Therefore, they must encourage then patients to take the pills with enough liquid, in supine position and have special attention to the elderly and those with any kind of esophageal disease.
Asunto(s)
Antibacterianos/efectos adversos , Doxiciclina/efectos adversos , Enfermedades del Esófago/inducido químicamente , Úlcera/inducido químicamente , Adulto , Anciano , Antiulcerosos/uso terapéutico , Enfermedades del Esófago/diagnóstico , Enfermedades del Esófago/tratamiento farmacológico , Esofagoscopía , Femenino , Humanos , Masculino , Factores de Riesgo , Sucralfato/uso terapéutico , Úlcera/diagnóstico , Úlcera/tratamiento farmacológicoRESUMEN
Se estudiaron en grupos de ratas Wistar, en stress por inmovilización más inmersión en agua a 18C, las groseras lesiones agudas gástricas sangrantes y su prevención con drogas citoprotectoras gástricas como: sucralfato, HOAI y Mg, magaldrato, hidrotalcita y misoprostol; asimismo, drogas antisecretoras gástricas como misoprostol (dosis antisecretora), somatostatina (octeotride), ranitidina, omeprazol y lanzoprazol. En otra experiencia, se estudió la secreción gástrica ácida en ratas con ligadura de píloro, donde fueron tratadas con las mismas drogas y dosis que en la experiencia anterior. Se comprobó que el modelo de stress 6 hs. dió una zona lesional gástrica de un 80 por ciento; el sucralfato, como droga citoprotectora, dio una protección parcial de la mucosa gástrica; en cambio, los bloqueantes de la bomba de protones, omeprazol y lanzoprazol dieron una zona gástrica cercana al 0 por ciento y por ende, postulamos su uso en terapia intensiva en la profilaxis de las lesiones agudas gástricas sangrantes en el stress. (AU)
Asunto(s)
Animales , Ratas , Femenino , Úlcera Gástrica/prevención & control , Gastritis/prevención & control , Mucosa Gástrica/patología , Sucralfato/administración & dosificación , Sucralfato/uso terapéutico , Hidróxido de Magnesio/uso terapéutico , Hidróxido de Magnesio/administración & dosificación , Hidróxido de Aluminio/administración & dosificación , Hidróxido de Aluminio/uso terapéutico , Misoprostol/administración & dosificación , Misoprostol/uso terapéutico , Somatostatina/administración & dosificación , Somatostatina/uso terapéutico , Ranitidina/administración & dosificación , Ranitidina/uso terapéutico , Omeprazol/administración & dosificación , Omeprazol/uso terapéutico , Ácido Gástrico/metabolismo , Estrés FisiológicoAsunto(s)
Humanos , Hemorragia Gastrointestinal/prevención & control , Antagonistas de los Receptores H2 de la Histamina/efectos adversos , Misoprostol/uso terapéutico , Sucralfato/uso terapéutico , Antiácidos/uso terapéutico , Factores de Riesgo , Estudios Prospectivos , Investigación/métodos , Enfermedad Aguda/terapia , Evaluación de Resultados de Intervenciones Terapéuticas/métodos , Hemorragia Gastrointestinal/epidemiología , Hemorragia Gastrointestinal/mortalidad , Antagonistas de los Receptores H2 de la Histamina/economía , Antiácidos/efectos adversos , Resultado del Tratamiento , AlgoritmosRESUMEN
Se estudiaron en grupos de ratas Wistar, en stress por inmovilización más inmersión en agua a 18C, las groseras lesiones agudas gástricas sangrantes y su prevención con drogas citoprotectoras gástricas como: sucralfato, HOAI y Mg, magaldrato, hidrotalcita y misoprostol; asimismo, drogas antisecretoras gástricas como misoprostol (dosis antisecretora), somatostatina (octeotride), ranitidina, omeprazol y lanzoprazol. En otra experiencia, se estudió la secreción gástrica ácida en ratas con ligadura de píloro, donde fueron tratadas con las mismas drogas y dosis que en la experiencia anterior. Se comprobó que el modelo de stress 6 hs. dió una zona lesional gástrica de un 80 por ciento; el sucralfato, como droga citoprotectora, dio una protección parcial de la mucosa gástrica; en cambio, los bloqueantes de la bomba de protones, omeprazol y lanzoprazol dieron una zona gástrica cercana al 0 por ciento y por ende, postulamos su uso en terapia intensiva en la profilaxis de las lesiones agudas gástricas sangrantes en el stress.